Endothelial binding sites for heparin. Specificity and role in heparin neutralization
- PMID: 2432885
- PMCID: PMC1147213
- DOI: 10.1042/bj2380847
Endothelial binding sites for heparin. Specificity and role in heparin neutralization
Abstract
The specificity of endothelial binding sites for heparin was investigated with heparin fractions and fragments differing in their Mr, charge density and affinity for antithrombin III, as well as with heparinoids and other anionic polyelectrolytes (polystyrene sulphonates). The affinity for endothelial cells was estimated by determining I50 values in competition experiments with 125I-heparin. We found that affinity for endothelial cells increases as a function of Mr and charge density (degree of sulphation). Binding sites are not specific receptors for heparin. Other anionic polyelectrolytes, such as pentosan polysulphates and polystyrene sulphonates, competed with heparin for binding to endothelial cells. Fractions of standard heparin with high affinity for antithrombin III also had greater affinity for endothelium. However, these two properties of heparin (affinity for antithrombin III and affinity for endothelial cells) could be dissociated. Oversulphated heparins and oversulphated low-Mr heparin fragments had lower anticoagulant activity and higher affinity for endothelial cells than did their parent compounds. Synthetic pentasaccharides, bearing the minimal sequence for binding to antithrombin III, did not bind to endothelial cells. Binding to endothelial cells involved partial neutralization of heparin. Bound heparin exhibited only 5% and 7% of antifactor IIa and antifactor Xa specific activity, respectively. In the presence of 200 nM-antithrombin III, and in the absence of free heparin, a limited fraction (approx. 30%) of bound heparin was displaced from endothelial cells during a 1 h incubation period. These data suggested that a fraction of surface-bound heparin could represent a pool of anticoagulant.
Similar articles
-
Anticoagulant properties of heparin preparations from different animal sources with equivalent high affinity for antithrombin III.J Biochem. 1984 Mar;95(3):619-26. doi: 10.1093/oxfordjournals.jbchem.a134650. J Biochem. 1984. PMID: 6725227
-
Neutralization and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin-binding domain of S protein/vitronectin.J Biol Chem. 1987 Sep 5;262(25):12247-53. J Biol Chem. 1987. PMID: 2442161
-
Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics.Thromb Res. 1987 Feb 1;45(3):211-22. doi: 10.1016/0049-3848(87)90189-7. Thromb Res. 1987. PMID: 2821646
-
Rationale behind the development of low molecular weight heparin derivatives.Semin Thromb Hemost. 1985 Jan;11(1):13-6. doi: 10.1055/s-2007-1004352. Semin Thromb Hemost. 1985. PMID: 2579436 Review.
-
Heparin, its fractions, fragments and derivatives. Some newer perspectives.Semin Thromb Hemost. 1985 Jan;11(1):1-9. doi: 10.1055/s-2007-1004350. Semin Thromb Hemost. 1985. PMID: 3919446 Review.
Cited by
-
Identification of a heparin-binding protein using monoclonal antibodies that block heparin binding to porcine aortic endothelial cells.Biochem J. 1995 Oct 15;311 ( Pt 2)(Pt 2):461-9. doi: 10.1042/bj3110461. Biochem J. 1995. PMID: 7487882 Free PMC article.
-
Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.Drugs. 1992 Nov;44(5):858-88. doi: 10.2165/00003495-199244050-00010. Drugs. 1992. PMID: 1280570 Review.
-
The effects of heparin on the adhesion of human peripheral blood mononuclear cells to human stimulated umbilical vein endothelial cells.Br J Pharmacol. 2001 Oct;134(4):827-36. doi: 10.1038/sj.bjp.0704321. Br J Pharmacol. 2001. PMID: 11606323 Free PMC article.
-
Inhibition of leucocyte elastase by heparin and its derivatives.Biochem J. 1988 Jun 1;252(2):515-9. doi: 10.1042/bj2520515. Biochem J. 1988. PMID: 3415672 Free PMC article.
-
Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?Exp Hematol Oncol. 2013 Aug 8;2:21. doi: 10.1186/2162-3619-2-21. eCollection 2013. Exp Hematol Oncol. 2013. PMID: 23927414 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical